Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Hormonal antineoplastic drugs
N-Desmethylenzalutamide
Другие языки:

    N-Desmethylenzalutamide

    Подписчиков: 0, рейтинг: 0
    N-Desmethylenzalutamide
    Desmethylenzalutamide.svg
    Clinical data
    Other names Desmethylenzalutamide; Norenzalutamide
    Drug class Nonsteroidal antiandrogen
    Pharmacokinetic data
    Protein binding 95%
    Elimination half-life 7.8 days
    Identifiers
    • 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluorobenzamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEBI
    Chemical and physical data
    Formula C20H14F4N4O2S
    Molar mass 450.41 g·mol−1
    3D model (JSmol)
    • CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)N)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
    • InChI=1S/C20H14F4N4O2S/c1-19(2)17(30)27(11-4-3-10(9-25)14(7-11)20(22,23)24)18(31)28(19)12-5-6-13(16(26)29)15(21)8-12/h3-8H,1-2H3,(H2,26,29)
    • Key:JSFOGZGIBIQRPU-UHFFFAOYSA-N

    N-Desmethylenzalutamide is a nonsteroidal antiandrogen (NSAA) and the major metabolite of enzalutamide, an NSAA which is used as a hormonal antineoplastic agent in the treatment of metastatic prostate cancer. It has similar activity to that of enzalutamide and, with enzalutamide therapy, circulates at similar concentrations to those of enzalutamide at steady state.N-Desmethylenzalutamide is formed from enzalutamide in the liver by the cytochrome P450 enzymes CYP2C8 and CYP3A4. It has a longer terminal half-life than enzalutamide (7.8 days versus 5.8 days).



    Новое сообщение